Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;3(6):315-24.
doi: 10.1177/1759720X11415306.

Diagnosis and treatment of the idiopathic inflammatory myopathies

Diagnosis and treatment of the idiopathic inflammatory myopathies

David J Gazeley et al. Ther Adv Musculoskelet Dis. 2011 Dec.

Abstract

The idiopathic inflammatory myopathies (IIMs) are rare disorders with the unifying feature of proximal muscle weakness. These diseases include polymyositis(PM), dermatomyositis (DM) and inclusion body myositis (IBM) as the most common. The diagnosis is based on the finding of weakness on exam, elevated muscles enzymes, characteristic histopathology of muscle biopsies, electromyography abnormalities and rash in DM. Myositis-specific antibodies have been helpful in defining subsets of patients with different responses to treatment and prognosis. The cornerstone of therapy is corticosteroids with the addition of other immunosuppressives in severe or refractory disease or patients with intolerable side effects. IBM is particularly difficult to treat but is more slowly progressive as compared with PM or DM. There is still a great need to find more effective and less-toxic therapies.

Keywords: dermatomyositis; idiopathic inflammatory myopathies; inclusion body myositis; polymyositis.

PubMed Disclaimer

Conflict of interest statement

Dr Gazeley has no conflicts of interest to declare. Dr Cronin was a subinvestigator in the Rituximab in Myositis (RIM) Trial. She has no other conflicts of interest to declare.

References

    1. Alexanderson H. (2009) Exercise effects in patients with adult idiopathic inflammatory myopathies. Curr Opin Rheumatol 21: 158–163 - PubMed
    1. Amato A.A., Barohn R.J. (2009) Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiat 80: 1186–1193 - PubMed
    1. Badrising U.A., Maat-Schieman M.L., Ferrari M.D., Zwinderman A.H., Wessels J.A.M., Bredveld F.C., et al. (2002) Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 51: 369–372 - PubMed
    1. Bazzani C., Cavazzana I., Ceribelli A., Vizzardi E., Dei Cas E., Franceschini F. (2010) Cardiological features in idiopathic inflammatory myopathies. J Cardiovasc Med 11: 906–911 - PubMed
    1. Bendewald M.J., Wetter D.A., Li X., Davis M.D. (2010) Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population- based study in Olmsted County, Minnesota. Arch Dermatol 146: 26–30 - PMC - PubMed

LinkOut - more resources